SG10201403869TA - Organoarsenic compounds and methods for the treatment of cancer - Google Patents

Organoarsenic compounds and methods for the treatment of cancer

Info

Publication number
SG10201403869TA
SG10201403869TA SG10201403869TA SG10201403869TA SG10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA SG 10201403869T A SG10201403869T A SG 10201403869TA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
methods
organoarsenic compounds
organoarsenic
Prior art date
Application number
SG10201403869TA
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Solasia Pharma K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solasia Pharma K K filed Critical Solasia Pharma K K
Publication of SG10201403869TA publication Critical patent/SG10201403869TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201403869TA 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer SG10201403869TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
SG10201403869TA true SG10201403869TA (en) 2014-10-30

Family

ID=41707414

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201403869TA SG10201403869TA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201810449XA SG10201810449XA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201810450QA SG10201810450QA (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Country Status (19)

Country Link
US (4) US20110269697A1 (en)
EP (2) EP3388111B1 (en)
JP (5) JP5933896B2 (en)
KR (3) KR20170103023A (en)
CN (2) CN102149432A (en)
AU (1) AU2009282972A1 (en)
BR (1) BRPI0918407A2 (en)
CA (1) CA2734650A1 (en)
DK (2) DK2321012T3 (en)
ES (2) ES2901426T3 (en)
HK (2) HK1254607A1 (en)
IL (1) IL211153A0 (en)
MX (1) MX2011001800A (en)
NZ (1) NZ591181A (en)
PT (2) PT2321012T (en)
RU (1) RU2534606C2 (en)
SG (3) SG10201810449XA (en)
WO (1) WO2010021928A1 (en)
ZA (1) ZA201101216B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617305B (en) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 Compounds and methods for the treatment of cancer
CN104151397A (en) * 2014-07-03 2014-11-19 北京大学 Novel thiabicyclo organic arsenide compound and synthesis method thereof, as well as application in anti-tumor field
JP6413969B2 (en) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 Dispersion for forming solar shading body and solar shading body using the dispersion
JPWO2019220961A1 (en) * 2018-05-18 2020-05-28 ソレイジア・ファーマ株式会社 Crystalline form of darinaparcin alkali metal salt and/or inorganic acid addition salt and preparation thereof
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (en) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 Method and device for detecting purity of flue-cured tobacco, electronic equipment and storage medium

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
PT2018858E (en) 1997-10-15 2011-03-24 Polarx Biopharmaceuticals Inc Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic trioxide
BR9814857A (en) 1997-11-10 2001-12-26 Sloan Kettering Inst Cancer Processes for treating leukemia, solid cancer, leukemia, lymphoma or solid tumors in a human, and for making a sterile pharmaceutical composition, and the respective sterile pharmaceutical composition
CN1233476A (en) 1998-04-24 1999-11-03 陆道培 Medicine for treating acute leukemia, and method for preparing same
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
KR20030014208A (en) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 Administration of a thiol-based chemoprotectant compound
DE10132625A1 (en) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Process, computer program product and device system for visually checking image data
AU2003207455B2 (en) 2002-01-07 2007-09-20 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (en) 2004-07-16 2014-11-01 Texas A & M Univ Sys Organic arsenic compounds, uses of the same in treating cancer and pharmaceutical compositions comprising the same
JP4994374B2 (en) 2005-07-29 2012-08-08 ジオファーム オンコロジー, インコーポレイテッド Compounds and methods for treating cancer
CN101395166B (en) * 2006-01-13 2014-07-09 得克萨斯州A&M大学系统 Compounds and methods for the treatment of cancer
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
AU2008276451A1 (en) * 2007-07-17 2009-01-22 Zalicus Inc. Treatments of B-cell proliferative disorders
TW200914048A (en) * 2007-07-17 2009-04-01 Combinatorx Inc Combinations for the treatment of B-cell proliferative disorders
CN101903029B (en) * 2007-11-02 2012-09-26 Zio医药肿瘤学公司 Combination therapy with organic arsenicals
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
JP5933896B2 (en) 2016-06-15
EP3388111B1 (en) 2021-09-29
US11324714B2 (en) 2022-05-10
KR20180103194A (en) 2018-09-18
US11324713B2 (en) 2022-05-10
CN104800828A (en) 2015-07-29
NZ591181A (en) 2012-09-28
BRPI0918407A2 (en) 2015-11-24
US20150231107A1 (en) 2015-08-20
JP2012500271A (en) 2012-01-05
EP2321012A1 (en) 2011-05-18
JP6315841B2 (en) 2018-04-25
US10842769B2 (en) 2020-11-24
MX2011001800A (en) 2011-04-04
US20110269697A1 (en) 2011-11-03
PT3388111T (en) 2021-12-23
ZA201101216B (en) 2011-10-26
DK2321012T3 (en) 2018-12-03
ES2901426T3 (en) 2022-03-22
EP2321012B1 (en) 2018-10-10
US20210038557A1 (en) 2021-02-11
DK3388111T3 (en) 2021-12-06
US20210038556A1 (en) 2021-02-11
RU2011110392A (en) 2012-09-27
IL211153A0 (en) 2011-04-28
ES2703740T3 (en) 2019-03-12
JP2014148552A (en) 2014-08-21
AU2009282972A1 (en) 2010-02-25
SG10201810449XA (en) 2018-12-28
HK1212218A1 (en) 2016-06-10
EP2321012A4 (en) 2011-10-05
JP5976036B2 (en) 2016-08-23
KR20170103023A (en) 2017-09-12
RU2534606C2 (en) 2014-11-27
JP2017002081A (en) 2017-01-05
JP2018039853A (en) 2018-03-15
KR20110058818A (en) 2011-06-01
WO2010021928A1 (en) 2010-02-25
EP3388111A1 (en) 2018-10-17
JP2015120755A (en) 2015-07-02
CA2734650A1 (en) 2010-02-25
CN102149432A (en) 2011-08-10
HK1254607A1 (en) 2019-07-26
SG10201810450QA (en) 2018-12-28
PT2321012T (en) 2019-01-11

Similar Documents

Publication Publication Date Title
LT2303021T (en) Compounds for the treatment of cancer
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL213070A0 (en) Methods for the treatment of infections and tumors
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
EP2150270A4 (en) Methods and compositions for the treatment of cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL226363A0 (en) Compounds and methods for the treatment of cancer
EP2214485A4 (en) Methods for treatment of cancer
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0809046D0 (en) Cancer treatment
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0604114D0 (en) Combinations for the treatment of cancer
GB0712513D0 (en) Treatment of cancer